Correlation of pet standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning

被引:131
作者
Hong, Robert
Halama, James
Bova, Davide
Sethi, Anil
Emami, Bahman
机构
[1] Loyola Univ, Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA
[2] Loyola Univ, Med Ctr, Dept Radiol, Div Nucl Med, Maywood, IL 60153 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 67卷 / 03期
关键词
radiotherapy; positron emission tomography (PET); standard uptake value (SUV); target delineation; NSCLC;
D O I
10.1016/j.ijrobp.2006.09.039
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To develop standardized correlates of [F-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) standard uptake value (SUV) to computed tomography (CT)-based window and levels. Methods and Materials: Nineteen patients with non-small-cell lung cancer who underwent imaging with positron emission tomography (PET) and CT were selected. A method of standardizing SUV within CT planning software was developed. A scale factor, determined by a sensitivity calibration of the PET scanner, converts voxel counts to activity per gram in tissue, allowing SUVs to be correlated to CT window and levels. A method of limiting interobserver variations was devised to enhance "edges" of regions of interest based on SUV thresholds. The difference in gross tumor volumes (GTVs) based on CT, PET SUV >= 2.5, and regions of 40% maximum SUV were analyzed. Results: The mean SUV was 9.3. Mean GTV volumes were 253 cc for CT, 221 cc for SUV : 2.5, and 97 cc for SUV40%Max. Average volume difference was -259% between >= 2.5 SUV and CT and -162% between SUV40%Max and CT. Percent difference between GTV >= 2.5 SUV and SUV40%Max remained constant beyond SUV > 7. For SUVs 4-6, best correlation among SUV thresholds occurred at volumes near 90 cc. Mean percent change from GTVs contoured according to CT (GTV CT) was -260% for GTV2.5 and -162% for GTV40% Max. Using the SUV40% Max threshold resulted in a significant alteration of volume in 98% of patients, while the SUV2.5 threshold resulted in an alteration of volume in 58% of patients. Conclusions: Our method of correlating SUV to W/L thresholds permits accurate displaying of SUV in coregistered PET/CT studies. The optimal SUV thresholds to contour GTV depend on maximum tumor SUV and volume. Best correlation occurs with SUVs > 6 and small volumes < 100 cc. At SUVs > 7, differences between the SUV threshold filters remain constant. Because of variability in volumes obtained by using SUV40%Max, we recommend using SUV >= 2.5 for radiotherapy planning in non-small-cell lung cancer. (c) 2007 Elsevier Inc.
引用
收藏
页码:720 / 726
页数:7
相关论文
共 33 条
[1]   Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer [J].
Armstrong, J ;
Raben, A ;
Zelefsky, M ;
Burt, M ;
Leibel, S ;
Burman, C ;
Kutcher, G ;
Harrison, L ;
Hahn, C ;
Ginsberg, R ;
Rusch, V ;
Kris, M ;
Fuks, Z .
RADIOTHERAPY AND ONCOLOGY, 1997, 44 (01) :17-22
[2]  
BAYNE M, 2005, LUNG CANCER S3, V49, pS74
[3]   Defining a radiotherapy target with positron emission tomography [J].
Black, QC ;
Grills, IS ;
Kestin, LL ;
Wong, CYO ;
Wong, JW ;
Martinez, AA ;
Yan, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1272-1282
[4]   Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer [J].
Bradley, J ;
Thorstad, WL ;
Mutic, S ;
Miller, TR ;
Dehdashti, F ;
Siegel, BA ;
Bosch, W ;
Bertrand, RJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01) :78-86
[5]   Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT:: The impact of 18FDG-hybrid PET fusion [J].
Caldwell, CB ;
Mah, K ;
Ung, YC ;
Danjoux, CE ;
Balogh, JM ;
Ganguli, SN ;
Ehrlich, LE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (04) :923-931
[6]   Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial [J].
Dillman, RO ;
Herndon, J ;
Seagren, SL ;
Eaton, WL ;
Green, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1210-1215
[7]  
Erdi YE, 1997, CANCER, V80, P2505, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO
[8]  
2-F
[9]   Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET) [J].
Erdi, YE ;
Rosenzweig, K ;
Erdi, AK ;
Macapinlac, HA ;
Hu, YC ;
Braban, LE ;
Humm, JL ;
Squire, OD ;
Chui, CS ;
Larson, SM ;
Yorke, ED .
RADIOTHERAPY AND ONCOLOGY, 2002, 62 (01) :51-60
[10]   Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer [J].
Furuse, K ;
Fukuoka, M ;
Kawahara, M ;
Nishikawa, H ;
Takada, Y ;
Kudoh, S ;
Katagami, N ;
Ariyoshi, Y .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2692-2699